Immunophotonics

About Immunophotonics

Immunophotonics, Inc. is a private, clinical-stage biotechnology firm established in 2008, pioneering a field it terms "Interventional Immuno-Oncology". The company was co-founded by Lu Alleruzzo, who serves as CEO, and Tomas Hode, the Chief Innovation Officer. Alleruzzo's background combines a bachelor's degree in bioengineering and an MBA from the University of Missouri, with prior experience at firms like Cerner and HP. Hode holds a Ph.D. in astrobiology from Stockholm University and has over a decade of experience in the medical laser device industry. The company's genesis was serendipitous, stemming from an unexpected lab result where a viscous substance, later identified as the lead asset IP-001, caused tumors in an experiment to disappear.

The company's core focus is on transforming routine, minimally invasive tumor destruction procedures, such as thermal ablation, into personalized, systemic cancer immunotherapies. Its business model is centered on the research, clinical development, and eventual commercialization of its proprietary drug platform. As a clinical-stage entity, its operations are capital-intensive, funded through multiple financing rounds, including a significant Series B that raised $21.4 million, contributing to a total of over $28 million raised from investors like Johnson & Johnson Innovation and Zubizoom. The primary clients are medical institutions and oncology practices that perform tumor ablations.

The lead asset, IP-001, is a proprietary, injectable carbohydrate polymer (glycan polymer) designed to be administered directly into the site of a tumor immediately following an ablation procedure. This procedure leaves behind dead tumor tissue and a host of tumor-specific antigens. IP-001's unique physicochemical properties allow it to act like a depot, holding this antigenic material at the site and preventing its rapid clearance. Simultaneously, it potently stimulates the innate immune system, recruiting and activating antigen-presenting cells (APCs). This dual action facilitates a robust training of the patient's adaptive immune system, which then dispatches killer T-cells to not only clear the treated site but also to seek out and destroy metastatic tumors elsewhere in the body, potentially creating long-term immunity. The company has successfully completed multiple Phase 1b/2a clinical trials, including the INJECTABL-1 and SAKK 66/17 studies, across Europe and the US, evaluating IP-001 in various advanced solid tumors like colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma. The company's intellectual property is protected by patents in over 40 countries, including a key composition of matter patent in the U.S. valid until at least 2033.